Silvercorp Metals Inc. (NYSE:SVM)
Silvercorp Metals Inc. (NYSE:SVM), ended its previous trading session at $4.18 showing a loss of -0.17 or -3.91 percent with respect to the price of $4.35 when stock market opened. The company traded 2.29 Million shares over the course of the trading day. Giving the average volume of 2.53 Million over the course of 3 consecutive months. Which signifies a pretty good change over the time with its shares outstanding of 172.69 Million.
Silvercorp Metals Inc. (NYSE:SVM) is currently trading Higher than its price target which is set to $3.52 by the analyst. The stock is -29.51% Below its 1-Year High which is $5.93. SVM has a difference of 178.67% from its 1 year low which stands at $1.50. The company is currently rated by analyst who are keeping a close eye on the stock as 2. Where 1 means Buy, 2.5 meaning Hold and 5 as Sell.
Silvercorp Metals Inc. (NYSE:SVM) Performance Snapshot
The stock performed exceptionally bad in the previous week which depicts an decrease of 1.46 percent in the shares price. The company added about 20.11% in its share price over 1-Month. While taking about the performance of the stock over 1-year interval is 100.96 Percent. SVM currently shows -26.28% as its year to date performance.
Silvercorp Metals Inc. (NYSE:SVM) Price Insight
The stock needs to grow about $-0.66 to reach its price target. In order to seek the stock’s directional movements, 20-Days, 50 Days and 200-Days moving averages are 4.53%, 16.99% and -1.86 percent respectively. The stock trades about 2.36 percent of its Float giving its total shares Outstanding are 172.69 Million. SVM lost about -12.37 percent in 6 months showing its Average True Range of 0.36. The company currently has a RSI and Beta of 53.66 and 1.33.
While talking about Silvercorp Metals Inc. (NYSE:SVM) valuation ratios, the stock trades with a P/S and P/B of 4.13 and 1.9 which is significantly better and attractive as compared to its peers.
Pain Therapeutics, Inc. (NASDAQ:PTIE)
Performance Indicators of Pain Therapeutics, Inc. (NASDAQ:PTIE)
Pain Therapeutics, Inc. (NASDAQ:PTIE) Analytical Review